A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the intravenous treatment of adult patients with severe community-acquired bacterial pneumonia and admitted to the intensive care unit

Trial Profile

A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the intravenous treatment of adult patients with severe community-acquired bacterial pneumonia and admitted to the intensive care unit

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Cx 611 (Primary)
  • Indications Sepsis
  • Focus Adverse reactions
  • Acronyms SEPCELL
  • Sponsors TiGenix
  • Most Recent Events

    • 12 Apr 2018 In Q1 2018, the independent Data Monitoring Committee (iDMC), recommended to continue the study with no changes in the protocol, after reviewing the safety and efficacy data from the first 20 randomized patients, according to a Tigenix media release.
    • 12 Aug 2017 This trial has been suspended in Spain.
    • 06 Apr 2017 According to a TiGenix media release, data from this trial are expected in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top